HONG KONG – Chinese regulators have clarified the legal consequences of data falsification in new drug and medical device applications, alarming the industry – both applicants for registration and research institutions – by raising falsification to the level of a criminal law violation.
HONG KONG – Lumosa Therapeutics Co. Ltd. is exploring the neurology and pain management space with a model designed for biopharmas without huge drug discovery budgets.
Two of China's biggest pharmaceutical companies, Shanghai Fosun Pharmaceutical Co. Ltd. and Shanghai Pharmaceuticals Holding Co. Ltd., have confirmed bids for a stake in Atlanta-based Arbor Pharmaceuticals LLC in a deal that could be worth upwards of $2 billion, depending on the valuation.
HONG KONG – Lumosa Therapeutics Co. Ltd. is exploring the neurology and pain management space with a model designed for biopharmas without huge drug discovery budgets.
Two of China's biggest pharmaceutical companies, Shanghai Fosun Pharmaceutical (Group) Co. Ltd. and Shanghai Pharmaceuticals Holding Co. Ltd., have confirmed bids for a stake in Atlanta-based Arbor Pharmaceuticals LLC in a deal that could be worth upward of $2 billion, depending on the valuation.
HONG KONG – Hong Kong-listed company Uni-Bio Science Group Ltd. now has Chinese conglomerate Heungkong Group as a strategic shareholder as it works to expand its distributing network, build biotech incubation centers and search for international M&A deals.
HONG KONG – After a prolonged negotiation process, China has secured drug prices that are, in some cases, much lower than those in Europe and other developed markets.
HONG KONG – The Chinese drug registration authority has approved the phase III trial of a cancer drug in the first open meeting it ever held, clearing the way for late-stage testing of an oncolytic immunotherapy drug developed by Korean biopharma company Sillajen Inc. and its Chinese partner, Lee’s Pharmaceutical Holdings Ltd.
HONG KONG – The Chinese drug registration authority has approved the phase III trial of a cancer drug in the first open meeting it ever held, clearing the way for late-stage testing of an oncolytic immunotherapy drug developed by Korean biopharma company Sillajen Inc. and its Chinese partner, Lee's Pharmaceutical Holdings Ltd.
HONG KONG – Hong Kong-listed company Uni-Bio Science Group Ltd. now has Chinese conglomerate Heungkong Group as a strategic shareholder as it works to expand its distributing network, build biotech incubation centers and search for international M&A deals.
